Kei Kishimoto

Company: Selecta Bioscience

Job title: CSO

Seminars:

Overcoming Immunogenicity Challenges of AAV Gene Therapy Vectors 2:30 pm

AAV gene therapy elicits a complex immune response, involving innate and adaptive B and T cell responses that can affect safety, efficacy and the ability to re-dose AAV vectors Pre-existing anti-AAV neutralizing antibodies preclude many patients from being able to receive AAV gene therapy I will present unpublished data from studies in mice, nonhuman primates…Read more

day: Track A - Day 1 PM